Rundu Shares: Announcement on abnormal stock trading fluctuations
Securities code: 002923 Securities abbreviation: Rundu Shares Announcement number: 2026-005
Zhuhai Rundu Pharmaceutical Co., Ltd.
Announcement on abnormal stock trading fluctuations
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Abnormal fluctuations in stock trading
The cumulative deviation from the closing price increase of Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") stock for three consecutive trading days (January 29, January 30, and February 2, 2026) exceeded 20%. According to the relevant regulations of the Shenzhen Stock Exchange, it is a case of abnormal stock trading fluctuations.
2. Explanation of the company’s concerns and verification
In response to the abnormal fluctuations in the company's stock, the company's board of directors conducted a comprehensive self-examination and verified the company's controlling shareholders and actual controllers on relevant issues through written and telephone inquiries. The verification situation is as follows:
There is no need to correct or supplement the information previously disclosed by the company.
The company has not found any undisclosed material information related to the company that has received high market attention recently reported by public media.
The company currently has a Class 1 innovative drug (chemical drug) higenamine hydrochloride injection (specification: 2ml:2.5mg) and its raw materials, and its drug review work is in order. Innovative drugs have the characteristics of long R&D cycles, heavy investment, and high risks. There is uncertainty about whether the drug can be approved for marketing, the time when it is approved for marketing, and the production and sales situation after marketing. It will not have a significant impact on the company's performance in the short term.
There have been no major changes in the company’s current operating conditions and internal and external operating environments.
The company, its controlling shareholders and actual controllers, and shareholders holding more than 5% of the shares have no major matters that should be disclosed but have not been disclosed by the company, or major matters that are in the planning stage.
During the period of abnormal stock fluctuations, there is no behavior of controlling shareholders or actual controllers buying and selling company stocks.
The company does not violate fair information disclosure regulations.
3. Whether there is an explanation of information that should be disclosed but has not been disclosed
The company's board of directors confirms that the company currently does not have any undisclosed matters that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations, or any planning, negotiations, intentions, agreements, etc. related to the matter; the board of directors is also not informed that the company has undisclosed information that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations that will have a greater impact on the trading price of the company's stock and its derivatives; there is no need to correct or supplement the information disclosed by the company in the previous period.
4. Risk warning
After self-examination, the company did not violate fair information disclosure.
The company disclosed the "2025 Performance Forecast" on January 30, 2026. As of the disclosure date of this announcement, the above performance forecast does not need to be revised. For the company's specific financial data in 2025, please refer to the company's 2025 annual report. The Company's unpublic periodic performance information is not provided to third parties other than the accounting firms that audit the Company.
The company disclosed the "Pre-Disclosure Announcement on the Reduction of Shareholdings by Shareholders Holding More than 5% of the Shares and Some Directors and Senior Managers" on December 15, 2025 (Announcement Number: 2025-060). As of the disclosure date of this announcement, the shareholding reduction plans of Mr. Li Xi, Mr. Liu Jie and Ms. You Chunyan have not yet been completed. The company's board of directors will urge Mr. Li Xi, Mr. Liu Jie and Ms. You Chunyan to implement the shareholding reduction plan legally and compliantly in accordance with relevant regulations and requirements, and to perform their information disclosure obligations in a timely manner.
The company's board of directors solemnly reminds investors: "China Securities Journal", "Securities Times", "Securities Daily", "Shanghai Securities News" and cninfo.com (www.cninfo.com.cn) are the company's designated information disclosure media. All the company's information is subject to the information published in the above designated media. Investors are requested to invest rationally and pay attention to risks.
Announcement is hereby made.
Board of Directors of Zhuhai Rundu Pharmaceutical Co., Ltd.
February 3, 2026